These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 22982441)

  • 1. Oncostatin M is a growth factor for Ewing sarcoma.
    David E; Tirode F; Baud'huin M; Guihard P; Laud K; Delattre O; Heymann MF; Heymann D; Redini F; Blanchard F
    Am J Pathol; 2012 Nov; 181(5):1782-95. PubMed ID: 22982441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GP130/OSMR is the only LIF/IL-6 family receptor complex to promote osteoblast differentiation of calvaria progenitors.
    Malaval L; Liu F; Vernallis AB; Aubin JE
    J Cell Physiol; 2005 Aug; 204(2):585-93. PubMed ID: 15751050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The AB loop and D-helix in binding site III of human Oncostatin M (OSM) are required for OSM receptor activation.
    Adrian-Segarra JM; Schindler N; Gajawada P; Lörchner H; Braun T; Pöling J
    J Biol Chem; 2018 May; 293(18):7017-7029. PubMed ID: 29511087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant Activation of OSM and LIF Receptor by a Dual-Specific hlOSM Variant Confers Cardioprotection after Myocardial Infarction in Mice.
    Lörchner H; Adrian-Segarra JM; Waechter C; Wagner R; Góes ME; Brachmann N; Sreenivasan K; Wietelmann A; Günther S; Doll N; Braun T; Pöling J
    Int J Mol Sci; 2021 Dec; 23(1):. PubMed ID: 35008777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of osteoblast markers and induction of the glial fibrillary acidic protein by oncostatin M in osteosarcoma cells require PKCdelta and STAT3.
    Chipoy C; Berreur M; Couillaud S; Pradal G; Vallette F; Colombeix C; Rédini F; Heymann D; Blanchard F
    J Bone Miner Res; 2004 Nov; 19(11):1850-61. PubMed ID: 15476586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncostatin M-specific receptor mediates inhibition of breast cancer cell growth and down-regulation of the c-myc proto-oncogene.
    Liu J; Spence MJ; Wallace PM; Forcier K; Hellström I; Vestal RE
    Cell Growth Differ; 1997 Jun; 8(6):667-76. PubMed ID: 9186000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncostatin M (OSM) cytostasis of breast tumor cells: characterization of an OSM receptor beta-specific kernel.
    Underhill-Day N; Heath JK
    Cancer Res; 2006 Nov; 66(22):10891-901. PubMed ID: 17108126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of osteogenesis in mesenchymal stem cells by activated monocytes/macrophages depends on oncostatin M signaling.
    Guihard P; Danger Y; Brounais B; David E; Brion R; Delecrin J; Richards CD; Chevalier S; Rédini F; Heymann D; Gascan H; Blanchard F
    Stem Cells; 2012 Apr; 30(4):762-72. PubMed ID: 22267310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.
    Hensel T; Giorgi C; Schmidt O; Calzada-Wack J; Neff F; Buch T; Niggli FK; Schäfer BW; Burdach S; Richter GH
    Oncotarget; 2016 Jan; 7(2):1451-63. PubMed ID: 26623725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of short-form oncostatin M receptor as a decoy receptor in lung adenocarcinomas.
    Chen D; Chu CY; Chen CY; Yang HC; Chiang YY; Lin TY; Chiang IP; Chuang DY; Yu CC; Chow KC
    J Pathol; 2008 Jul; 215(3):290-9. PubMed ID: 18491353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1.
    Giorgi C; Boro A; Rechfeld F; Lopez-Garcia LA; Gierisch ME; Schäfer BW; Niggli FK
    Oncotarget; 2015 Oct; 6(30):28895-910. PubMed ID: 26336820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EWS-FLI1-mediated suppression of the RAS-antagonist Sprouty 1 (SPRY1) confers aggressiveness to Ewing sarcoma.
    Cidre-Aranaz F; Grünewald TG; Surdez D; García-García L; Carlos Lázaro J; Kirchner T; González-González L; Sastre A; García-Miguel P; López-Pérez SE; Monzón S; Delattre O; Alonso J
    Oncogene; 2017 Feb; 36(6):766-776. PubMed ID: 27375017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphoproteomic profiling reveals IL6-mediated paracrine signaling within the Ewing sarcoma family of tumors.
    Anderson JL; Titz B; Akiyama R; Komisopoulou E; Park A; Tap WD; Graeber TG; Denny CT
    Mol Cancer Res; 2014 Dec; 12(12):1740-54. PubMed ID: 25092916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Murine Oncostatin M Acts via Leukemia Inhibitory Factor Receptor to Phosphorylate Signal Transducer and Activator of Transcription 3 (STAT3) but Not STAT1, an Effect That Protects Bone Mass.
    Walker EC; Johnson RW; Hu Y; Brennan HJ; Poulton IJ; Zhang JG; Jenkins BJ; Smyth GK; Nicola NA; Sims NA
    J Biol Chem; 2016 Oct; 291(41):21703-21716. PubMed ID: 27539849
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncostatin M acting via OSMR, augments the actions of IL-1 and TNF in synovial fibroblasts.
    Le Goff B; Singbrant S; Tonkin BA; Martin TJ; Romas E; Sims NA; Walsh NC
    Cytokine; 2014 Aug; 68(2):101-9. PubMed ID: 24767864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncostatin M-specific receptor expression and function in regulating cell proliferation of normal and malignant mammary epithelial cells.
    Liu J; Hadjokas N; Mosley B; Estrov Z; Spence MJ; Vestal RE
    Cytokine; 1998 Apr; 10(4):295-302. PubMed ID: 9617575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Coexpression of oncostatin M and its receptors and evidence for STAT3 activation in human ovarian carcinomas.
    Savarese TM; Campbell CL; McQuain C; Mitchell K; Guardiani R; Quesenberry PJ; Nelson BE
    Cytokine; 2002 Mar; 17(6):324-34. PubMed ID: 12061840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of IL-6/gp130 family receptor expression reveals that in contrast to astroglia, microglia lack the oncostatin M receptor and functional responses to oncostatin M.
    Hsu MP; Frausto R; Rose-John S; Campbell IL
    Glia; 2015 Jan; 63(1):132-41. PubMed ID: 25103368
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blocking the road, stopping the engine or killing the driver? Advances in targeting EWS/FLI-1 fusion in Ewing sarcoma as novel therapy.
    Kovar H
    Expert Opin Ther Targets; 2014 Nov; 18(11):1315-28. PubMed ID: 25162919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oncostatin M is a differentiation factor for myeloid leukemia cells.
    Bruce AG; Hoggatt IH; Rose TM
    J Immunol; 1992 Aug; 149(4):1271-5. PubMed ID: 1380037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.